Original Publication Date: 3 February, 2014
Publication / Source: Future Oncology
Authors: Ramon Salazar, Julieta Grasselli, Cristina Santos & Josep Tabernero
The addition of bevacizumab to the treatment of metastatic colorectal cancer patients reaches its tenth anniversary this year accompanied by somewhat mixed feelings from our perspective and the lack of unanimity among oncologists dealing with this deadly disease. While it has definitely become a new option in many treatment combinations in the advanced disease setting, its strategic positioning is complex and controversial. While some advocate for its wider use in first- and second-line chemotherapy combinations, even continuing it beyond progression, others are more cautious and recommend a more restricted use. Its efficacy has been validated in multiple Phase III clinical trials with a number of chemotherapy backbone regimens, which provide solid evidence confirming its consistent biological activity and clinical relevance [1–6].